Xanthine derivatives as selective hm74a agonists

A compound of formula (I):

• pharmaceutically acceptable derivatives thereof,
• wherein:
• R1 represents -(alkylene)m-X-(alkylene)n-Y;
• R2 represents C1-6 alkyl, which optionally is substituted by one or more groups independently selected from cycloalkyl, C1-6 haloalkyl, halogen, —CN or —OR4;
• R3 represents halogen;
• wherein:
• m and n is number of carbon atoms in the alkylene chain;
• X is a group selected from heteroaryl or heterocyclyl;
• Y is a group selected from aryl, heteroaryl and O-aryl;
• which optionally is substituted by one or more groups independently selected from C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, halogen, —(CH2)qNR5R7, —(CH2)q—(O)p—(CH2)q—N(R5)C(O)OR8, —(CH2)q—N(R5)C(O)R8, —(CH2)q—(O)p—(CH2)q—C(O)NR5R6, —(CH2)q—N(R5)C(O)NR5R6, —(CH2)q—C(O)N((CH2)mOH)R5, —(CH2)q—N(R5)—S(O)2R8, —CH2—S(O)2NR5R6, —C1-6 haloalkyl, —OCF3, —OCH(F)2, —OCH2F, —C(O)OR5, —OR5, —R8CN, CN, —SO2R9, —(CH2)nheteroaryl, —(CH2)nheterocyclyl, —(CH2)ncycloalkyl, —(CH2)ncycloalkenyl, or —(CH2)naryl;
• R4 represents a group selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —(CH2)n cycloalkyl, —(CH2)n cycloalkenyl, —(CH2)n heterocyclyl, —(CH2)n aryl, or —(CH2)n heteroaryl;
• R5 and R6 are independently selected from hydrogen or C1-4 alkyl;
• R7 represents a group selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,
• —(CH2)t cycloalkyl, —(CH2)n cycloalkenyl, —(CH2)t heterocyclyl, —(CH2)t aryl, or —(CH2)t heteroaryl;
• R8 represents C1-4 alkyl;
• R9 represents a group selected from C1-6 alkyl C2-6 alkenyl, C2-6 alkynyl, —(CH2)n cycloalkyl, —(CH2)ncycloalkenyl, —(CH2)nheterocyclyl, —(CH2)n aryl, —(CH2)nheteroaryl, or CN;
• m represents an integer selected from 3 and 4;
• n represents an integer selected from 0 and 1;
• p represents an integer selected from 0 and 1;
• q represents an integer selected from 0, 1 and 2;
• and
• t represents an integer selected from 1 and 2.